EmeraMed
Manufacturing · Ireland · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Trinity House Charleston Rd, Dublin, Sou...Website
www.emeramed.comRevenue
$7.2 MillionIndustry
About EmeraMed
EmeraMed Ltd is a biotechnology firm focused on developing Emeramide (also known as Irminix), a lipophilic metal chelator and antioxidant that can cross the blood-brain barrier. The company is currently seeking FDA approval for Emeramide as a treatment for mercury poisoning and has conducted preclinical studies for various other applications. EmeraMed aims to partner with strategic investors to support the clinical development and commercialization of its innovative solutions targeting heavy metal toxicity and oxidative stress. Their research highlights the potential of Emeramide in improving health outcomes for patients exposed to toxic metals.Explore more
EmeraMed Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to EmeraMed
Compare insights from companies similar to EmeraMed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
EmeraMed Tech Stack
A closer look at the technologies used by EmeraMed
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding EmeraMed
Sign Up For FreeTo access detailed company insights
EmeraMed Ltd is a biotechnology firm focused on developing Emeramide (also known as Irminix), a lipophilic metal chelator and antioxidant that can cross the blood-brain barrier. The company is currently seeking FDA approval for Emeramide as a treatment for mercury poisoning and has conducted preclinical studies for various other applications. Emera... Read More
